美國諾瓦瓦克斯Novavax, Inc. www.novavax.com
Novavax公司是致力于新型的、高效的傳染病疫苗臨床階段研究的前沿性企業(yè)，這些新型疫苗比現有的疫苗更具安全性和有效性。通過公司的病毒樣顆粒載體專利（VLP）和Novasome®輔助技術，我們正在研發(fā)對抗H5N1型禽流感病毒、季節(jié)性流感和其它病毒性傳染病的疫苗。Novavax公司的微粒疫苗能更好地匹配因為缺乏遺傳性抗性導致疾病的致病病毒，以達到在更低的劑量時，就可以為機體提供強大的潛在免疫保護作用。同時，專用的便攜式生產系統(tǒng)，可以快速生產大量疫苗， 這一獨一無二的優(yōu)越條件，可以更好地滿足全球公共衛(wèi)生的需要。

Novavax, Inc. is a clinical stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP based potent, recombinant vaccines utilizing a new and efficient manufacturing approach.
Our world-class scientific team is using virus-like particle (VLP) technology to tackle influenza viruses – including avian strains that have the potential to cause a pandemic outbreak. Our team has created vaccines designed to protect against various circulating strains of avian influenza as well as seasonal flu, Respiratory Syncytial Virus (RSV) and Varicella Zoster Virus (VZV). We have validated our approach in animals and are now in clinical testing with our pandemic and seasonal influenza vaccine.
Our vision is a holistic approach to controlling the spread of disease. Using a unique portable manufacturing system that allows for rapid mass production, our long-term goal is to be able to rapidly deliver a customized vaccine in the midst of a pandemic.
Novavax plans to apply its particle-based vaccine approach to other viral diseases beyond influenza.